SCHEMBL1890902

SCHEMBL1890902

NC1COc2ccccc2O1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 1/20 0.53
ADRA2A P08913 2/20 0.47
ADRA1A P35348 2/20 0.47
HTR1A P08908 1/20 0.47
DRD1 P21728 1/20 0.47
TBXA2R P21731 1/20 0.47
SLC6A2 P23975 1/20 0.47
DRD3 P35462 1/20 0.47
CA2 P00918 4/20 0.45
ABCG2 Q9UNQ0 1/20 0.44
ITGB2 P05107 1/20 0.44
ICAM1 P05362 1/20 0.44
ITGAL P20701 1/20 0.44
ALOX5 P09917 1/20 0.44
HTT P42858 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1B P35368 1/20 0.43
SCN1A P35498 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8493018 0.81 SMN1; SMN2 (0.61) NISCHADRA2AADRA1AHTR1ADRD1
SCHEMBL896833 0.81 SMN1; SMN2 (0.61) NISCHADRA2AADRA1AHTR1ADRD1
SCHEMBL2061817 0.78 ITGB2 (0.52) NISCHABCG2ITGB2ICAM1ITGAL
SCHEMBL18365855 0.78 ABCG2 (0.50) NISCHADRA2AADRA1AHTR1ADRD1
SCHEMBL17816166 0.77 NISCH (0.48) NISCHADRA2AADRA1AHTR1ADRD1
SCHEMBL4773404 0.75 CHRNB4 (0.50) CA2
SCHEMBL1567701 0.74 NISCH (0.50) NISCHADRA2AADRA1AHTR1ADRD1
SCHEMBL14322211 0.74 NISCH (0.32) NISCH
SCHEMBL5731128 0.73 ABCG2 (0.50) NISCHADRA2AADRA1AHTR1ADRD1
SCHEMBL20241876 0.73 ADRA2A (0.54) NISCHADRA2AADRA1AHTR1AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260069599-A1 INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 AND PHOSPHOINOSITIDE 3-KINASE UNIV NEBRASKA (US) 2026-03-12 US claimed
WO-2024050505-A2 INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 AND PHOSPHOINOSITIDE 3-KINASE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2024-03-07 WO claimed
US-20150031705-A1 OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS OCULARIS PHARMA LLC (US) 2015-01-29 US claimed
EP-1755591-A4 OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS OCULARIS PHARMA INC (US) 2007-11-07 EP claimed
EP-1755591-A2 OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS Ocularis Pharma, Inc. (US) 2007-02-28 EP claimed
WO-2005123093-A2 OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS OCULARIS PHARMA, INC. (US) 2005-12-29 WO claimed
US-20050080056-A1 Alpha 1 antagonist; reduces pupil size in dim light, but less reduction in pupil size in bright light; artificial tear; tamsulosin, urapidil Ocuphire Pharma, Inc. 2005-04-14 US claimed
CN-116710783-A Detection of target analytes by cross-spray ESI mass spectrometry 豪夫迈·罗氏有限公司 2023-09-05 CN disclosed
CN-116323568-A Detection of target analytes by nanoESI mass spectrometry 豪夫迈·罗氏有限公司 2023-06-23 CN disclosed
CN-106167483-B It can be used for compound, composition and the method for cholesterol mobilization 塞伦尼斯医疗控股有限公司 2019-02-15 CN disclosed
CN-107011359-A Compound, composition and the method mobilized available for cholesterol 塞伦尼斯医疗控股有限公司 2017-08-04 CN disclosed
CN-103442714-B Compounds, compositions and methods useful for cholesterol mobilization 塞伦尼斯医疗控股有限公司 2017-04-19 CN disclosed
CN-106167483-A Can be used for compound, compositions and method that cholesterol is mobilized 塞伦尼斯医疗控股有限公司 2016-11-30 CN disclosed
US-5578697-A DIELECTRIC POLYMERS FOR ELECTRONICS KABUSHIKI KAISHA TOSHIBA (JP) 1996-11-26 US disclosed
EP-0429535-A1 FUNGICIDAL BENZODIOXANE AMINE DERIVATIVES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-06-05 EP disclosed
EP-0429535-A1 FUNGICIDAL BENZODIOXANE AMINE DERIVATIVES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-06-05 EP disclosed
EP-0359400-A1 Fungicidal benzodioxane amine derivatives E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-03-21 EP disclosed
EP-0359400-A1 Fungicidal benzodioxane amine derivatives E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-03-21 EP disclosed
WO-1990002122-A1 FUNGICIDAL BENZODIOXANE AMINE DERIVATIVES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-03-08 WO disclosed
WO-1990002122-A1 FUNGICIDAL BENZODIOXANE AMINE DERIVATIVES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260069599-A1 INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 AND PHOSPHOINOSITIDE 3-KINASE BRD4, BRD3, BRPF3 NISCH 4675/4885ADRA2A 2798/4885ADRA1A 2298/4885
US-20150031705-A1 OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS ADRA1D, ADRA1A, ADRA1B NISCH 578/4885ADRA2A 5/4885ADRA1A 2/4885
US-20050080056-A1 Alpha 1 antagonist; reduces pupil size in dim light, but less reduction in pupil size in bright light; artificial tear; tamsulosin, urapidil ADRA1A, ADRA1D, ADRA2A NISCH 432/4885ADRA2A 3/4885ADRA1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.